BIOMAT Database Logo BIOMAT Database Logo

Melatonin attenuates ifosfamide-induced Fanconi syndrome in rats. 2004

Goksel Sener, and Ozer Sehirli, and Berrak C Yegen, and Sule Cetinel, and Nursal Gedik, and Abdullah Sakarcan
School of Pharmacy and Department of Pharmacology, School of Medicine, Marmara University, Istanbul, Turkey. gokselsener@hotmail.com

Regarding the mechanisms of ifosfamide (IFO)-induced nephrotoxicity and hemorrhagic cystitis, several hypotheses have been put forward, among which oxidative stress and depletion of glutathione (GSH) are suggested. This investigation elucidates the role of free radicals in IFO-induced toxicity and the protection by melatonin. Wistar albino rats were injected intraperitoneally with saline (0.9% NaCl; control-C group), melatonin (Mel group; 10 mg/kg daily for 5 days) or ifosfamide (50 mg/kg daily for 5 days; IFO group) or IFO + Mel. On the 5th day (120 hr) after the first IFO dose, animals were killed by decapitation and trunk blood was collected. Kidney and bladder tissues were obtained for biochemical and histological analysis. Urine was collected 24 hr before the rats were killed. The results demonstrated that IFO induced a Fanconi syndrome (FS) characterized by wasting of sodium, phosphate, and glucose, along with increased serum creatinine and urea. Melatonin markedly ameliorated the severity of renal dysfunction induced by IFO with a significant decrease in urinary sodium, phosphate, and glucose and increased creatinine excretion. Moreover, melatonin significantly improved the IFO-induced GSH depletion, malondialdehyde accumulation and neutrophil infiltration in both renal and bladder tissues. In the kidney, Na+,K+ -ATPase activity which was significantly reduced by IFO, was increased with melatonin treatment. Increased collagen contents of the kidney and bladder tissues by IFO treatment were reversed back to the control levels with melatonin. Our results suggest that IFO causes oxidative damage in renal and bladder tissues and melatonin, via its antioxidant effects, protects these tissues. These data suggest that melatonin may be of therapeutic use in preventing acquired FS due to IFO toxicity.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008550 Melatonin A biogenic amine that is found in animals and plants. In mammals, melatonin is produced by the PINEAL GLAND. Its secretion increases in darkness and decreases during exposure to light. Melatonin is implicated in the regulation of SLEEP, mood, and REPRODUCTION. Melatonin is also an effective antioxidant.
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D005198 Fanconi Syndrome A hereditary or acquired form of generalized dysfunction of the PROXIMAL KIDNEY TUBULE without primary involvement of the KIDNEY GLOMERULUS. It is usually characterized by the tubular wasting of nutrients and salts (GLUCOSE; AMINO ACIDS; PHOSPHATES; and BICARBONATES) resulting in HYPOKALEMIA; ACIDOSIS; HYPERCALCIURIA; and PROTEINURIA. De Toni-Debre-Fanconi Syndrome,Lignac-Fanconi Syndrome,Proximal Renal Tubular Dysfunction,Renal Fanconi Syndrome,Adult Fanconi Syndrome,Fanconi Bickel Syndrome,Fanconi Renotubular Syndrome,Fanconi Syndrome with Intestinal Malabsorption and Galactose Intolerance,Fanconi Syndrome without Cystinosis,Fanconi-Bickel Syndrome,Glycogen Storage Disease XI,Glycogenosis, Fanconi Type,Hepatic Glycogenosis with Amino Aciduria and Glucosuria,Hepatic Glycogenosis with Fanconi Nephropathy,Hepatorenal Glycogenosis with Renal Fanconi Syndrome,Idiopathic De Toni-Debre-Fanconi Syndrome,Luder-Sheldon Syndrome,Neonatal De Toni-Debre-Fanconi Syndrome,Primary Toni-Debre-Fanconi Syndrome,Pseudo-Phlorizin Diabetes,Toni-Debre-Fanconi Syndrome,Bickel Syndrome, Fanconi,Diabete, Pseudo-Phlorizin,Diabetes, Pseudo-Phlorizin,Fanconi Syndrome, Adult,Fanconi Syndrome, Renal,Fanconi Type Glycogenosis,Fanconi-Bickel Syndromes,Lignac Fanconi Syndrome,Luder Sheldon Syndrome,Pseudo Phlorizin Diabetes,Pseudo-Phlorizin Diabete,Renotubular Syndrome, Fanconi,Syndrome, Adult Fanconi,Syndrome, Fanconi,Syndrome, Fanconi Bickel,Syndrome, Fanconi Renotubular,Syndrome, Fanconi-Bickel,Syndrome, Lignac-Fanconi,Syndrome, Luder-Sheldon,Syndrome, Renal Fanconi,Syndromes, Fanconi-Bickel
D005260 Female Females
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D005978 Glutathione A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. Reduced Glutathione,gamma-L-Glu-L-Cys-Gly,gamma-L-Glutamyl-L-Cysteinylglycine,Glutathione, Reduced,gamma L Glu L Cys Gly,gamma L Glutamyl L Cysteinylglycine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Goksel Sener, and Ozer Sehirli, and Berrak C Yegen, and Sule Cetinel, and Nursal Gedik, and Abdullah Sakarcan
L-Histidinol attenuates Fanconi syndrome induced by ifosfamide in rats.
January 1999, Experimental nephrology,
Goksel Sener, and Ozer Sehirli, and Berrak C Yegen, and Sule Cetinel, and Nursal Gedik, and Abdullah Sakarcan
Glycine attenuates Fanconi syndrome induced by maleate or ifosfamide in rats.
March 1996, Kidney international,
Goksel Sener, and Ozer Sehirli, and Berrak C Yegen, and Sule Cetinel, and Nursal Gedik, and Abdullah Sakarcan
Ifosfamide-induced Fanconi syndrome.
June 1989, Lancet (London, England),
Goksel Sener, and Ozer Sehirli, and Berrak C Yegen, and Sule Cetinel, and Nursal Gedik, and Abdullah Sakarcan
Ifosfamide-induced Fanconi syndrome.
June 1995, The Annals of pharmacotherapy,
Goksel Sener, and Ozer Sehirli, and Berrak C Yegen, and Sule Cetinel, and Nursal Gedik, and Abdullah Sakarcan
Ifosfamide induced Fanconi syndrome.
December 2011, BMJ case reports,
Goksel Sener, and Ozer Sehirli, and Berrak C Yegen, and Sule Cetinel, and Nursal Gedik, and Abdullah Sakarcan
Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice.
November 1999, Journal of ethnopharmacology,
Goksel Sener, and Ozer Sehirli, and Berrak C Yegen, and Sule Cetinel, and Nursal Gedik, and Abdullah Sakarcan
Taurine attenuates fanconi syndrome induced by ifosfamide without compromising its antitumor activity.
January 1998, Oncology research,
Goksel Sener, and Ozer Sehirli, and Berrak C Yegen, and Sule Cetinel, and Nursal Gedik, and Abdullah Sakarcan
Partial Fanconi Syndrome Induced by Ifosfamide.
January 2019, Cureus,
Goksel Sener, and Ozer Sehirli, and Berrak C Yegen, and Sule Cetinel, and Nursal Gedik, and Abdullah Sakarcan
Partial Fanconi syndrome induced by ifosfamide.
January 2019, Proceedings (Baylor University. Medical Center),
Goksel Sener, and Ozer Sehirli, and Berrak C Yegen, and Sule Cetinel, and Nursal Gedik, and Abdullah Sakarcan
Ifosfamide-induced Fanconi syndrome with diabetes insipidus.
March 2014, The Korean journal of internal medicine,
Copied contents to your clipboard!